key: cord-0782761-a3mun7f8
authors: Singh, Hitesh; Jakhar, Renu; Sehrawat, Neelam
title: Designing Spike protein (S-Protein) based multi-epitope peptide vaccine against SARS COVID-19 by immunoinformatics
date: 2020-11-16
journal: Heliyon
DOI: 10.1016/j.heliyon.2020.e05528
sha: 16c7c081924a3eca3a6b604a38cd8a04dd38ed7a
doc_id: 782761
cord_uid: a3mun7f8

The outbreak of COVID-19 was originated from China, responsible for Several Acute Respiratory Syndrome (SARS). Scientists are forced to develop vaccine and effective drugs to control COVID-19 infection. To develop effective vaccine for SARS – COVID 19, immunoinformatics and computational approaches could helps to design successful vaccine against this biggest danger for humanity. Here we used various in – silico approaches to designed vaccine against COVID-19. To develop vaccine, we target S- protein, expressed on the virus surface plays important role in COVID-19 infection. We identified 12 B-cell, 9 T-helper and 20 Cytotoxic T-cell epitope based on criteria of selection. The predicted epitopes were link simultaneously with GPGPG & AAY linkers. The β-defensin was used as adjuvant, linked with selected epitope by using EAAAK linker. For vaccine construct justification we analysed its immunogenicity, allergenicity and physiochemical properties. Our study revealed that vaccine was non toxic, immunogenic and antigenic in nature and covers 98.6% of world population, important for vaccine effectively. In- silico cloning was used to analyse its expression in vector. Molecular docking was performed to study the interaction of construct with TLR (TLR3, TLR4, and TLR9) molecules. The immune simulation was conducted and conformed that our vaccine constructs can induces both acquired and humoral immunity effectively against COVID-19 at very low concentration, but along with bioinformatics study we need to conduct experiment in laboratory to validate its safety and effectiveness.

In December 2019, an unspecified viral infection was recognized in seafood market of Wuhan city, China named as (2019-nCoV). On 30 January 2020 Chinese outbreak, WHO (World Health Organisation) declared it as public health emergency for international concern because of its high transmission rate (WHO, 2020) . On 16 Aug 2020 the total numbers of cases for COVID-19 are 21,026, 758 and 755,786 deaths globally (WHO, 2020) . The high mortality and transmission of COVID-19 infection causes huge burden on health organisation and economy of the countries (WHO, 2020; Kock et al., 2020) and condition was remains hypercritical throughout the world. The Drugs are used for the treatment of COVID-19 infection are Remdesivir, Choloroquinine, Lopinavir, Rotonavir and its combination, but it become a question which drug work effectively against it (Agostini et al., 2018; Aguiar et al., 2018; Cvetkovic et al., 2003) . The COVID-19 infection and its high rate of transmission challenges scientific research and industries to develop effective vaccine and drugs, but since now there is no effective vaccine or drug to fight against it. Several medical control measures have been taken to control Corona infection, pre-diagnosis, isolation, effective treatment. For individual WHO advises for hygiene and to avoid crowded places. All these control measure are just to control transmission of COVID-19 infection, not permanent solution.

SARS-Cov 2 is member of beta corona virus, causing pneumonia. COVID-19 is a enveloped virus with single stranded RNA, belonging corona viridae family can cause infection in mammals, birds and humans (Tortorici et al., 2019; . The whole genome of SARS -CoV 2 was sequenced , approximately 29.9 kb. The availability of the genome had opened the opportunity to develop vaccine against this devastating disease.

The genome of the SARS -CoV 2 encoded for total (6) (7) (8) (9) (10) (11) open reading frame (Cui et al., 2019) (orf1ab, S protein, ORF3a, envelope protein, membrane glycoprotein, ORF6, ORF7a, RF8 protein, nucleocapsid phosphoprotein, ORF10). From all these protein we target the Sprotein which plays important role in virus infection in humans. It is outer membrane spike glycoprotein which undergoes its glycosylation (Xionag et al., 2018) . S protein act as primary interacting protein with host target e. g ACE2, CD26, and other cell receptors) all these play important role in cell adhesion and virulence (Song et al., 2018; Millet et al., 2012) . After adhesion the genomic RNA released into cytoplasm and virus enter into the host cell, inside the host cell genomic RNA translated into two polypeptide and structural protein and start replication (Bergmann et al., 2006) .

The spike protein composed of two domains, S1 is receptor binding domain (RBD) supposed that SARS -CoV 2 used angiotensin-converting enzyme 2 (ACE2) receptor to infect human host and another S2 domain responsible for the fusion of viral membrane and host cell membrane. Along with these ACE2 pathway SARS -CoV 2 may use some other pathway for infection because ACE2 expressed in lungs monocytes and macrophages (Bonavia et al., 2003; Li et al., 2003; Yan et al., 2020; Sun et al., 2020) . The importance of the S protein during infection and virulence make it an ideal target to develop vaccine for SARS -CoV 2.

An effective potential vaccine against COVID-19 has not yet been designed, so here we are trying to designed epitope based vaccine, to activate both innate and acquired immunity.

Epitopes are segment of protein which is antigenic in nature and activate immunity against pathogen (Sutton et al., 2018) . Immediately after the pathogen entry in human host APCs (antigen presenting cell) activates Cytotoxic T-cell to kill infected cell (Khan et al., 2018) .

Spike protein is antigenic in nature; hence we were detected large number of epitope for both B-cell and T-cell epitope.

Recently due the availability of advance immunoinformatics tool attracts the researchers to develop stable and effective vaccine against pathogenic diseases and it also reduces immunological experimental burden on model organism (Sharker et al., 2015) . These immunoinformatics tool provide reliable, accurate and rapid pathway to designed potential multiepitope vaccine against diseases e.g enterotoxigenic Bacteroides fragilis (Mahnoor Majid & Saadia Andle., 2019), Helicobacter Pylori (Khan et al., 2019) , Onchocerca volvulus (Shrey et al., 2019) and Cancer (Nezafat et al., 2015) , reliable than whole protein and attenuated pathogen which may couses hypersensitivity and other immunological response such local redness, swelling and pain or raise in body temperature after immunization. Based on previous immunoinformatic based multiepitope designed vaccine for other disease we applied the same approches for SARS-CoV2 . Here, S protein antigenic which is antigenic in nature was used as target to detect both B-cell and T-cell epitope to design a potential vaccine construct was formed. In-silico cloning was used to study its expression in expression vector; Molecular docking was performed to validate its efficiency to activate immune response and its stability. With the use of immunoinformatics tool validation we required, its affirmation experimentally in animal model and humans.

J o u r n a l P r e -p r o o f Sequence retrieval of S-protein and its antigenicity. The sequence of S-protein was retrieved from NCBI. Here, the selection of protein as target for vaccine development is based on its antigenicity and its importance in viral infection. The VaxiJen v2.0 server (Irini et al., 2005) was used to analyse its antigenicity, important factor to activate immunity against SARS -CoV 2. The graphical work flow for research was shown in Fig.1 .

Conformational and linear B-cell epitope prediction. B-cell lymphocytes plays very significant role in immunity response and produces long lasting immune response against the pathogen. To predict the accurate B-cell linear epitope we used BCPred and IEDB tool (Chou et al., 1978; Parker et al., 1986; Emini et al., 1985; Kolaker et al., 1990) . BCPred (Manzalawy et al., 2008; Saha et al., 2004) tool was based on SVM (Support Vector Machine) algorithm to predict B-cell linear epitope. The linear epitopes are selected based on its surface assesbility, flexibility, beta-turn and antigenicity. The methodology for the vaccine formulation against SERS -CoV 2 was represented in this work flow in sequential manner, First two step were for target protein sequence analysis and its antigenicity. Third step for the epitope selection, remaining was for the vaccine construct validation, its interaction with TLR's molecules and last one is immune profiling J o u r n a l P r e -p r o o f To predict Conformational B-cell epitope, Ellipro online server (Ponomarenko et al., 2008) was used. Ellipro selected the epitope based on Residue clustering algorithm along with Thorton's techniques. The standard used for the selection of conformational epitope was PI (Protrusion index: 0.5) score.

Cytotoxic T-cell epitope (CTL) prediction. The NetCTL 1.2 (Larsen et al., 2007) online sever was used to predict MHC 1 binding epitope. The prediction of epitope based on Cterminal cleavage and its TAP transport efficiency. These epitopes were selected based on threshold value (0.75). The immunogenicity of CTL epitope were also analysed using IEDB MHC I immunogenicity prediction tool (Calis et al., 2013) .

T-helper cell epitope prediction. IEDB MHCII tool (Wang et al., 2008) To calculate the population coverage covered with selected MHC I and MHC II epitopes, we used IEDB population coverage tool (Trott et al., 2010) .

Strategic views for development of vaccine construct. B-cell epitope were selected based on its criteria of selection and its allergenicity. The selection of T cell epitope (Cytotoxic Tcell epitope & T-helper based on its binding affinity for HLA molecules and immunogenicity. To construct multiple epitope vaccine, B-cell and T-helper cell epitopes were linked by GPGPG linker and CTL epitopes were linked with AAY linker. To enhance immune response we used β-defensin (Chen et al., 2000) as an adjuvant at C-terminal and linked with EAAAK linker. Polyhistidine-tag was adjoining at C-terminal of the vaccine construct.

Allergenicity and antigenicity profiling for vaccine construct. To conform whether the vaccine are not eliciting allergy, we use Allertop v 2.0 (Dimitrov et al., 2013) , worked on Auto cross covariance of protein sequence.

The antigenicity of the vaccine is important factor to activate immune response. Here we used Vaxijen v 2.0, to predict the antigenicity of vaccine construct. For antigencity prediction are based on pathogen specific and physiochemical properties of the proteins sequence.

Analysis of physiochemical properties of vaccine. To understand the vaccine response and its stability, the physiochemical properties of the vaccine construct were analysed with the use of online tool ProtParam (Gasteiger et al., 2005) . Some of the protein properties important for its antigenic nature, so we were focused to study some physiochemical properties e.g the amino acid composition, theoretical pI, GRAVY index, its instability index etc.

Secondary structure predictions for vaccine construct. To predict the secondary structure of the vaccine used SOPMA (Geourjon et al., 195) online software. The prediction of secondary structure based on the Homology Protein modelling

The secondary structure analysis was used to predict its solvent accessibility, transmembrane helix, globular region and βturn region which are the important factor for protein stability and for efficiency of vaccine.

The 3-D structure of the predicted vaccine was modelled by using the online server RaptorX (Kallberg et al., 2012) . The modelled structure was refined with the use of Galaxy refine tool online server (Ko et al., 2012) .

For Validation of refine 3-D structure, we used RAMPAGE (Lovell et al., 2003) and PROSA (Wiederstein et al., 2007) web online tool.

RAMPAGE is based on the Ramachandran plot (Hooft et al., 1997) to analyse the amino acid in favoured and unfavoured region.

Codon optimisation of vaccine. To reverse transcription and codon optimisation, we used Jcat online tool (Grote et al., 2005) to calculate GC contain and CAI score for maximum expression in vector. For maximum expression of query sequence GC content should be more than 50% and CAI score near to 1. For the immune response analysis simulation was done with the default parameter and single injection was used.

The sequence for Spike protein (Sprotein) was retrieved from NCBI, to predict of B-cell and T-cell epitope for the construction of multi epitope vaccine to fight against the COVID-19. The selection of S-protein for epitope prediction was based on its importance in viral infection and virulence.

with Vaxijen v 2.0 online immunoinformatics tool, results its antigenicity score 0.48, indicates it is a probable antigen to activate immunity against SARS -CoV 2.

and IEDB online tools were used for the selection of highly efficient B-cell linear epitope.

The selection was based on the antigenicity, its position in Beta turn, flexibility and solubility. Ellipro was used for the selection of conformational epitope. Based on the selection criteria there 12 B-cell epitope (Table 1) , to produce antibodies against SARS -CoV-2.

There are 9 T-helper (Table 2 ) and 20 Cytotoxic T-cell (Table 3) were selected for vaccine are non allergenic and immunogenic in nature. 

Population coverage for vaccine construct. The world population covered with the vaccine construct was 98.6% (Fig 3a, 3b) , calculating with the IEDB population coverage online tool.

The population coverage covered with the vaccine construct conformed that the designed vaccine was effective for most of the population throughout the world. and instability index (26.9) indicated that the vaccine construct was stable protein.

Secondary structure prediction. The secondary structure of the protein was predicted with the use of online server SOPMA. The analysis of secondary structure results that the vaccine composed of Alpha helix (23.5%), Random coil (44%), extended strand (25.2%) and betaturn (7.2%) shown (Fig 4) .

RaptorX was used to model the 3-D structure of the vaccine. The PDB templates (6VSB, 1FD3, 2LXO, 6M0J, 1BNB, 2RUN, 2DD8) were used for modelling its 3-D structure (Fig 6a) using tread modelling method. The structure of the Vaccine construct was refined with Galaxy refine tool.

The refined structure of the protein was validate with RAMPAGE, it confirmed that 89.8% amino acid are in favourable region, 5.5% are in allowed region and only 4.6% amino acid are in outlier region. PROSA -web (Fig 6b) oniline server used to analyse the standard of the structure. The Z score value of the refined structure was -5.66 and its Ramachandran plot (Fig 6c) and hydrophobicity plot (Fig 6d) show that most of the amino acid in vaccine are in favourable region. bp DNA sequence was used to input in vector. Jcat codon optimization results, the Codon optimization index (CI) was 1.0 and its GC contain was 58.08% which indicating that the vaccine construct was expressed at best level of expression in E. coli K12. The input sequence was cloned in pET-28a expression vector as shown in figure (Fig 7) . with PatchDock (https://bioinfo3d.cs.tau.ac.il/PatchDock/) and results for all three TLR's was shown in the table 4. Patchdock docking Score value and atomic contact energy conformed that our vaccine construct bind efficiently to TLR3, TLR4 & TLR9. Pymol and Discovery studio was used for the receptor and vaccine construct visualization Shown (Fig 9) .

MD simulation conform the thermo stability of the vaccine construct from RMSD (Root Mean Square Deviation) and RMSF (Root Mean Square Fluctuation) plot. Throughout processing, during simulation the value of RMSD value changed because of the backbone atomic movement. The high variation in RMSF peak for the residues indicating that vaccine construct is highly flexible (Fig 10) and compactness of the plot show its thermo stability. that the secondary and tertiary immune response is more prevalent than primary response.

The primary response mainly produces by B memory cell and IgM (Fig 11a) . The concentration of T helper cell (Fig 11c) , Cytokine and interleukins was considerably increased (Fig 11d) . The concentration of T-cytotoxic cell varied after administration of vaccine construct. To understand the efficiency of the vaccine construct various parameters were analysed to conform its allergenicity and antigenicity. The final construct was non-allergenic and J o u r n a l P r e -p r o o f antigenic in nature with antigenicity score 0.46. The total length of vaccine construct was 678 amino acid with molecular weight of 72.605 Kda. The isoelectric point for the vaccine construct was 9.57, indicating it is a basic in nature. The GRAVY index (0.065) and

instability index (26.9) indicated that the vaccine construct was stable protein.

The 3-D structure was assessed using RaptoX and refined with Galaxy refine -web server.

The RAMPAGE and PROSA web server were used for refined structure validation. Their 89.8% amino acids are in favourable region, 5.5% are in allowed region and only 4.6% amino acids are in outlier region. The Z score value of the refined structure was -5.66 and its

Ramachandran plot and hydrophobicity plot shows that most of the amino acid in vaccine are in favourable region.

The expression level of the vaccine construct in E.coli K12 analysed with the use of In-silico cloning and Jcat online tool revealed its maximum expression. The molecular docking stimulation of vaccine construct with TLR molecules (TLR3, TLR4, and TLR9) was done to assess its interaction. The vaccine construct was effectively bind with the receptors, showing strong binding affinity for TLR3 (-11.2 kcal/mol), TLR4 (-9.55 kcal/mol) and TLR9 (13.7 kcal/mol). The Immune simulation show that our vaccine construct is able to generate remarkable immune response just after administration at very low concentration of antigen.

The computational and immunoinformatics tool studies conformed that the vaccine construct is highly effective, stable and safe as a target for progressive vaccine against SARS -CoV2 and shows high rate of expression level in E-coli. Moreover, accurately the efficiency and validity of the vaccine understand after in-vitro experimental studies.

Here, our immunoinformatics based vaccine designed to fight against the SARS-CoV2. The potential novel multi-epitope designed vaccine able to generate both humoral and acquired immunity against COVID-19 because of high binding affinity with both HLA molecules. Our vaccine construct can generate remarkable immune response after injection of single dose of antigen. The various tools are used for its structure analysis and validation. The validation of vaccine construct for its safety, stability and its expression level confirmed by the using in-silico approaches. The results for the vaccine construct provide the deep view for vaccine designing and provide the base for experimentally verified vaccine to fight against the viral disease.

J o u r n a l P r e -p r o o f

Coronavirus susceptibility to the antiviral remdesivir (gs-5734) is mediatedby the viral polymerase and the proofreading exoribonuclease

Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity

Coronavirus infection of the central nervous system: host-virus stand-off

Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E

Properties of MHC class I presented peptides that enhance immunogenicity

Antimicrobial peptides human β-defensin (hBD)-and hBD-4 activate mast cells and increase skin vascular permeability

Prediction of the secondary structure of proteins from their amino acid sequence

Lopinavir/ritonavir: a review of its use in the management of HIV infection

AllerTOP-a server for in silico prediction of allergens

Predicting linear B-cell epitopes using string kernels

Induction of hepatitis A virusneutralizing antibody by a virus-specific synthetic peptide

Computational protein-ligand docking and virtual drug screening with the AutoDock suite

Protein identification and analysis tools on the ExPASy server

SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments

JCat: a novel tool to adapt codon usage of a target gene to its potential expression host

Objectively judging the quality of a protein structure from a Ramachandran plot

Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties

Templatebased protein structure modeling using the RaptorX web server

Computational identification, characterization and validation of potential antigenic

Immunoinformatics approaches to explore Helicobacter Pylori proteome (Virulence Factors) to design B and T cell multi-epitope subunit vaccine

GalaxyWEB server for protein structure prediction and refinement

2019-nCoV in context: lessons learned

A semi-empirical method for prediction of antigenic determinants on protein antigens

Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Structure validation by Cα geometry: ϕ, ψ and Cβ deviation

Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Designing a multi-epitopic vaccine against the

Ezrin interacts with the SARS coronavirus spike protein and restrains infection at the entry stage

Production of a novel multi-epitope peptide vaccine for cancer immunotherapy in TC-1 tumor-bearing mice

Ligand-based pharmacophore modeling, virtual screening and molecular docking studies for discovery of potential topoisomerase I inhibitors

New hydrophilicity scale derived from highperformance liquid chromatography peptide retention data: correlation of predicted surface residues with antigenicity and X-ray-derived accessible sites

ElliPro: a new structure-based tool for the prediction of antibody epitopes

BcePred:Prediction of Continuous B-Cell Epitopes in Antigenic Sequences Using Physico-chemical Properties

Post-Genomic Approaches in Drug and Vaccine Development

In-silico design of a multi-epitope vaccine candidate against onchocerciasis and related filarial diseases

Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2

Potential factors influencing repeated SARS outbreaks in China

Status of vaccine research and development for Helicobacter pylori

Structural basis for human coronavirus attachment to sialic acid receptors

AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach

ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins

World Health Organization

World Health Organization, Novel Coronavirus(2019-nCoV), Situation Report -12

World Health Organization: 2019-NCoV Outbreak Is an Emergency of International Concern. World Health Organization

A new coronavirus associated with human respiratory disease in China

Origin and evolution of pathogenic coronaviruses

Glycan shield and fusion activation of a delta coronavirus spike glycoprotein fine-tuned for enteric infections

Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2